Credit: Wikimedia Commons A treatment that involves genetically modifying the body’s own immune cells has been found to cut the risk of disease progression by 74 percent in people with a rare type of blood cancer, results showed Monday. Ciltacabtagene autoleucel—also known by its trade name Carvykti—was tested in a clinical trial involving 419 patients with multiple...
